COST-EFFECTIVENESS OF TP53 AND IGHV BIOMARKER TESTING PRIOR TO FIRST-LINE TREATMENT WITH NOVEL AGENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Vu, M. [1 ]
Degeling, K. [1 ]
Thompson, E. [2 ]
Blombery, P. [2 ]
Westerman, D. A. [2 ]
IJzerman, M. [1 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE141
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [41] Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.
    Senbetta, Mekre
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Romdhani, Hela
    Emond, Bruno
    Wang, Song
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients With CLL With Mutated IGHV and Without TP53 Aberration
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 6 - 8
  • [43] Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China
    Zhao, Jingping
    Jiang, Kaida
    Li, Qingwei
    Zhang, Yanlei
    Cheng, Yan
    Lin, Ziyi
    Xuan, Jianwei
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (05) : 439 - 446
  • [44] Cost-effectiveness of olanzapine as a first-line treatment: A response to comment
    Tunis, Sandra L.
    Faries, Douglas E.
    Nyhuis, Allen W.
    Kinon, Bruce J.
    Ascher-Svanum, Haya
    Lilly, Eli
    Aquila, Ralph
    VALUE IN HEALTH, 2006, 9 (05) : 358 - 358
  • [45] COST-EFFECTIVENESS OF OLANZAPINE IN THE FIRST-LINE TREATMENT OF SCHIZOPHRENIA IN CHINA
    Zhao, J.
    Jiang, K.
    Li, Q.
    Zhang, Y. L.
    Cheng, Y.
    Lin, Z.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S76 - S77
  • [46] COST-EFFECTIVENESS OF FIRST-LINE TREATMENT FOR INVASIVE ASPERGILOSIS IN COLOMBIA
    Castano, N.
    Reyes, J.
    Rodriguez, A.
    VALUE IN HEALTH, 2018, 21 : S227 - S227
  • [47] Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
    Davids, Matthew S.
    Chatterjee, Anuja
    Ravelo, Arliene
    Shapouri, Sheila
    Manzoor, Beenish S.
    Sail, Kavita
    Van de Wetering, Gijs
    Hallek, Michael
    BLOOD, 2019, 134
  • [48] IBRUTINIB TREATMENT DOESN'T INDUCE TP53 CLONAL EVOLUTION IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Cafforio, L.
    Cappelli, L. V.
    Del Giudice, I.
    Ilari, C.
    Raponi, S.
    De Propris, M. S.
    Mariglia, P.
    Piciocchi, A.
    Arena, V.
    Vignetti, M.
    Mauro, F. R.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2019, 104 : 1 - 2
  • [49] TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
    Del Giudice, Ilaria
    Cafforio, Luciana
    Cappelli, Luca Vincenzo
    Ilari, Caterina
    Raponi, Sara
    De Propris, Maria Stefania
    Mariglia, Paola
    Mauro, Francesca Romana
    Vignetti, Marco
    Guarini, Anna
    Foa, Robin
    BLOOD, 2018, 132
  • [50] Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
    Rigolin, Gian Matteo
    Olimpieri, Pier Paolo
    Summa, Valentina
    Celant, Simone
    Scarfo, Lydia
    Tognolo, Lucia
    Ballardini, Maria Pia
    Urso, Antonio
    Sessa, Mariarosaria
    Gambara, Silvia
    Cura, Francesca
    Fortini, Monica
    Ghia, Paolo
    Cuneo, Antonio
    Russo, Pierluigi
    BLOOD CANCER JOURNAL, 2023, 13 (01)
12345